The Worldwide Inhalation & Nasal Sprays Generic Drugs Industry is Expected to Reach $11.2 Billion by 2027 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Inhalation & Nasal Sprays Generic Drugs Market Intelligence Report – Global Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering.

The Global Inhalation & Nasal Sprays Generic Drugs Market is projected to reach USD 11,272.80 million by 2027 from USD 6,883.36 million in 2021, at a CAGR 8.56% during the forecast period.

Market Statistics:

The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available.

In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

• The Americas Inhalation & Nasal Sprays Generic Drugs Market size was estimated at USD 2,427.24 million in 2021, is expected to reach USD 2,604.45 million in 2022, and is projected to grow at a CAGR of 8.21% to reach USD 3,898.00 million by 2027.
• The Asia-Pacific Inhalation & Nasal Sprays Generic Drugs Market size was estimated at USD 1,577.49 million in 2021, is expected to reach USD 1,746.58 million in 2022, and is projected to grow at a CAGR of 9.32% to reach USD 2,693.80 million by 2027.
• The Europe, Middle East & Africa Inhalation & Nasal Sprays Generic Drugs Market size was estimated at USD 2,878.62 million in 2021, is expected to reach USD 3,108.31 million in 2022, and is projected to grow at a CAGR of 8.44% to reach USD 4,680.99 million by 2027.

Market Segmentation & Coverage:

The report on inhalation & nasal sprays generic drugs identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group’s economies and geographies can help gain business acumen for better strategic decision-making.

This market coverage across different industry verticals reveals the hidden truth about the players’ strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan.

This research report categorizes the inhalation & nasal sprays generic drugs to forecast the revenues and analyze the trends in each of the following sub-markets:

Indication:

• Allergic Rhinitis
• Asthma
• COPD

Age Group:

• Adults
• Children 2 to 5
• Children 6 to 12

Class:

• Allergy Blocker
• Anticholinergic
• Antihistamine
• Decongestant
• Mast Cell Inhibitor
• Nasal Steroid

Route:

• Inhalation
• Nasal Spray
• Tropical Lotion

DistributionChannel:

• Hospital Medical Store
• Online Pharmacy
• Pharmacy Retail

Region:

• Americas
  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
• Asia-Pacific
  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
• Europe, Middle East & Africa
  • France
  • Germany
  • Italy
  • Netherlands
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • United Arab Emirates
  • United Kingdom

Company Usability Profiles:

• AbbVie Inc.
• Akorn, Inc.
• Altaire Pharmaceuticals Inc.
• Apotex Inc.
• AstraZeneca PLC
• Beximco Pharmaceuticals Ltd.
• Catalent Pharma Solutions, Inc.
• Chiesi Farmaceutici S.p.A.
• Cipla Limited
• Hikma Pharmaceuticals PLC
• Nephron Pharmaceuticals Corporation
• Perrigo Company PLC
• Preferred Pharmaceuticals, Inc.
• Sandoz International GmbH
• Sheffield Pharmaceuticals, LLC
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.

For more information about this report visit https://www.researchandmarkets.com/r/9xy09d

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900